How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

GLP-1 vs non-GLP-1 anti-obesity medications: Changes in depression severity

calendar_today November 9, 2026 person Truveta staff domain truveta

Authors: Claire Campbell, PhD ⊕, Truveta, Inc, Bellevue, WA, USA Sarah Eng, MPH ⊕, Truveta, Inc, Bellevue, WA, USA Jeffrey Ratto, PhD ⊕, Truveta, Inc, Bellevue, WA, USA Katie Gilbert, MPH ⊕, Truveta, Inc, Bellevue, WA, USA Amy Austin, MHI ⊕, Truveta, Inc, Bellevue, WA, USA Ekaterina Khlystova, PhD ⊕, Truveta, Inc, Bellevue, WA, USA Sunny Guin, PhD ⊕, Truveta, Inc, Bellevue, WA, USA Vidya Venkataraman, MPH, PhD ⊕ Truveta, Inc, Bellevue, WA, USA Adults with obesity and depression who started a GLP-1 receptor agonist had a slightly larger decrease in depression severity (PHQ-9 score) over about s

open_in_new Read original post